This is a study to learn more about the safety and effectiveness of PT217 to treat advanced cancers. We are looking for patients with small cell lung cancer, large cell neuroendocrine cancer, neuroendocrine prostate cancer or gastroenteropancreatic neuroendocrine carcinomas to take part.
First, you will have a screening visit to make sure you are able to take part. If you can participate, you will receive the drug via an IV during each cycle.
Study Medication
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Jared Weiss
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Phase 1 Trials (all cancers))
23-1716